Key Figures Q2 2024
|
SEK m, unless otherwise stated |
2024 Apr-Jun | 2023 Apr-Jun | % Change | 2024 Jan-Jun | 2023 Jan-Jun | 2023 Jan-Dec |
| Net revenues | 154.0 | 157.7 | -2.3% | 293.2 | 316.8 | 638.8 |
| Cost of goods sold | -16.3 | -17.2 | -5.2% | -29.6 | -46.0 | -88.9 |
| Operating expenses | -153.5 | -153.4 | 0.1% | -284.2 | -343.0 | -659.5 |
| EBIT | -15.8 | -12.9 | -22.5% | -20.5 | -72.3 | -109.5 |
| EBIT margin, % | -10.3% | -8.2% | -25.6% | -7.0% | -22.8% | -17.1% |
| EBITDA | 5.0 | 5.6 | -10.7% | 20.9 | -35.4 | -32.5 |
| Earnings per share, before dilution, SEK | -1.04 | -0.37 | -181.1% | -1.30 | -2.22 | -3.73 |
| Earnings per share, after dilution, SEK | -1.04 | -0,37 | -181.1% | -1.30 | -2.22 | -3.73 |
| Cash flow from operating activities | -6.5 | -12.7 | 48.8% | -25.4 | -70.5 | -95.0 |
| Cash and invested funds | 139.7 | 251.1 | -44.4% | 139.7 | 251.1 | 171.0 |
Net revenues and EBIT per segment Q2 2024
|
|
Net Revenues |
EBIT |
||||||||
|
|
2024 |
2023 |
2024 Jan-Jun | 2023 Jan-Jun |
2023 |
2024 |
2023 |
2024 Jan-Jun | 2023 Jan-Jun |
2023 |
| Zubsolv® US product sales | 147.9 | 145.4 | 277.2 | 286.0 | 577.7 | - | - | - | - | - |
| Digital Mental Health Programs (DMHP) product sales | 0,0 | 0,0 | 0.0 | 0.1 | 0.1 | - | - | - | - | - |
| US Commercial– total | 147.9 | 145.4 | 277.2 | 286.0 | 577.7 | 36.0 | 37.6 | 67.9 | 75.3 | 152.3 |
| Abstral® royalties | 1.3 | 8.0 | 8.4 | 14.2 | 31.9 | - | - | - | - | - |
| Edluar® royalties | 3.3 | 4.0 | 6.0 | 5.2 | 10.8 | - | - | - | - | - |
| Zubsolv - ex US | 1.5 | 0.2 | 1.7 | 11.2 | 18.4 | - | - | - | - | - |
| HQ & Pipeline - total | 6.0 | 12.3 | 16.1 | 30.8 | 61.1 | -51.9 | -50.5 | -88.5 | -147.5 | -261.8 |
| Total | 154.0 | 157.7 | 293.2 | 316.8 | 638.8 | -15.8 | -12.9 | -20.5 | -72.3 | -109.5 |
Cash flow Q2 2024
SEK m |
2024 |
2023 |
2024 Jan-Jun | 2023 Jan-Jun |
2023 |
| Cash flow from operating activities | -6.5 | -12.7 | -25.4 | -70.5 | -95.0 |
| Investment activities | -2.7 | 125.1 | -3.8 | 208.3 | 200.8 |
| Financing activities | -48.0 | -14.0 | -4.7 | -25.5 | -70.1 |
| Cash flow (excl exchange rate differences) | -57.1 | 98.5 | -34.0 | 112.3 | 35.7 |
| Cash and cash equivalents | 139.7 | 251.1 | 139.7 | 251.1 | 171.0 |